<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Oppenheimer sees stronger growth at Boston Scientific</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Oppenheimer sees stronger growth at Boston Scientific</h1>
  <ul>
<li>They forecast annual growth of 11-13%, which was well above the broader medtech sector.</li>
<li>Boston Scientific was upgraded from Perform with a $125 price target.</li>
<li>Coverage of Tandem Diabetes was also assumed with an Outperform rating, though its target price was cut to $22 from $44.</li>
<li>Insulet was reiterated at Outperform and its target price raised to $365 from $324 following second-quarter results.</li>
<li>It could weigh on margins despite strong sales potential.</li>
<li>Investing.com -- Oppenheimer analysts shifted ratings on U.S.</li>
<li>Oppenheimer cited second-quarter performance and valuation adjustments.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/oppenheimer-sees-stronger-growth-boston-165057851.html">Source</a> · 2025-09-08T16:50:57+00:00</p>
</body>
</html>